Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.41 |
| ▸ | NT5E | P21589 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.38 |
| ▸ | ACP1 | P24666 | 2/20 | 0.38 |
| ▸ | PTPRF | P10586 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13637643 | 0.84 | ROCK2 (0.33) | LMNASMN1; SMN2GPBAR1NT5EPTPN1 | |
| SCHEMBL13637647 | 0.81 | TRPV1 (0.40) | PTPN1 | |
| SCHEMBL13628265 | 0.81 | GPBAR1 (0.64) | LMNASMN1; SMN2GPBAR1NT5E | |
| SCHEMBL13637784 | 0.80 | RORC (0.37) | GPBAR1PTPN1 | |
| SCHEMBL13637720 | 0.80 | RORC (0.38) | LMNANT5EPTPN1 | |
| SCHEMBL13637718 | 0.79 | RORC (0.38) | NT5EPTPN1 | |
| SCHEMBL13637724 | 0.78 | TRPV1 (0.41) | LMNAGPBAR1NT5EPTPN1 | |
| SCHEMBL13637788 | 0.78 | TRPV1 (0.38) | LMNANT5EPTPN1 | |
| SCHEMBL13637475 | 0.78 | RORC (0.38) | PTPN1 | |
| SCHEMBL13637675 | 0.78 | TRPV1 (0.42) | PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275583-A1 | ANTIVIRAL COMPOUNDS AND USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275583-A1 | ANTIVIRAL COMPOUNDS AND USE THEREOF | MAVS, ZC3HAV1, EIF2AK2 | LMNA 2620/4885SMN1; SMN2 1983/4885GPBAR1 3262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.